Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
October 21, 2013
The Early Movers
October 17, 2013
What happens now … is their oxygen for pricing growth other than retracement?
September 26, 2013
Rolling, not slipping
August 22, 2013
ReNeuron (RENE.L) Arthurian Life Science Group - $7.8 M equity investment
August 1, 2013
ReNeuron (RENE.L) wins £1.5 M UK Government grant for P2 stroke trial
September 11, 2012
Reneuron (RENE.L) Files 2 Clinical Trial Applications in UK
June 4, 2012
Athersys (ATHX), A Bridge too Far?
March 27, 2012
ReNeuron (RENE.L) Exercise of Warrants
December 19, 2011
RegMed Daily, Mid-Day, 12/19/11, everything works or nothing works, don't react to the moment
December 9, 2011
RegMed Daily, Mid-Day, 12/9/11, finally some sector movement
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.